• The clinical course of Crohn's disease
• The development of complications
• The emotional cost to patients
• Time to diagnosis

The clinical course of Crohn's disease

The graph below illustrates the lifetime clinical course of Crohn's disease (CD), breaking it down by disease state.¹

Five years after diagnosis, the proportion of patients:
      --in medical remission decreases to about 30%
      --with mild disease increases to 35%

• Only a small proportion of patients require surgery or are receiving corticosteroids or immunosuppressive medication
• A high proportion of patients are in "postsurgery remission"

Adapted from Silverstein et al.Gastroenterology.1999;117:49-57.
Click to enlarge

The development of complications

Most patients with high and chronic disease activity will develop a stricturing or penetrating (fistulizing) complication. This can impact hospitalization and surgical costs.²

The Kaplan-Meier chart below is from a retrospective study assessing the long-term disease progression of CD in more than 2000 patients. The graph illustrates the probability of patients remaining free of penetrating (upper curve), stricturing (middle), and inflammatory (lower curve) complications.²

Adapted from Cosnes J et al. Inflamm Bowel Dis. 2002;8:244-250.
Click to enlarge

The emotional cost to patients

The symptoms and complications of CD can greatly affect the quality of life of an individual, including physical and emotional well-being, social functioning, and self-image.³

In the Voices of Crohn's Survey, patients with Crohn's disease reported that the disease significantly impacts their personal and professional lives. In fact, 93% of Crohn's patients surveyed felt that the disease has an impact on their overall emotional well-being.⁴

Time to diagnosis

Patients with CD often wait more than 3 years before being properly diagnosed, often resulting in frustration to the patient. Additionally, 75% of patients felt that physicians and employers were in need of increased awareness about CD.⁴

Indication
CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.

NEXT: Clinical Manifestations and Complications »

Indication
CIMZIA is indicated for reducing signs and symptoms of Crohn's disease and maintaining clinical response in adult patients with moderately to severely active disease who have had an inadequate response to conventional therapy.

Important Safety Information
Serious and sometimes fatal side effects have been reported with CIMZIA, including tuberculosis (TB), bacterial sepsis, invasive fungal infections (such as histoplasmosis), and infections due to other opportunistic pathogens (such as Legionella or Listeria). Patients should be closely monitored for the signs and symptoms of infection during and after treatment with CIMZIA. Lymphoma and other malignancies also have been reported in children and adolescents. CIMZIA is not indicated for use in pediatric patients.

*The CIMZIA Co-Pay Savings Card Program is valid for out-of-pocket expenses for CIMZIA for up to 17 uses. The CIMZIA Co-Pay Savings Card Program is not valid for prescriptions that are reimbursed, in whole or part, under Medicare (including Medicare Part D), Medicaid, similar federal or state funded programs (including any state prescription drug assistance programs and the Government Health Insurance Plan available in Puerto Rico), private insurance in the Commonwealth of Massachusetts, or where otherwise prohibited by law. Product dispensed pursuant to program rules and federal and state laws. Claims should not be submitted to any public payor (i.e., Medicare, Medicaid, Medigap, Tricare, VA and DoD) for reimbursement. The parties reserve the right to amend or end this program at any time without notice.